OpGen (NASDAQ:OPGN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research report report published on Monday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Trading Up 3.0 %

Shares of OPGN stock opened at $2.37 on Monday. OpGen has a twelve month low of $1.65 and a twelve month high of $38.40. The stock has a fifty day simple moving average of $2.74 and a two-hundred day simple moving average of $4.13.

OpGen (NASDAQ:OPGN) last issued its earnings results on Monday, July 8th. The medical research company reported $0.21 earnings per share for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 997.34%. The business had revenue of $0.17 million during the quarter.

Institutional Investors Weigh In On OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp acquired a new position in shares of OpGen, Inc. (NASDAQ:OPGN) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned about 2.63% of OpGen at the end of the most recent reporting period. 2.68% of the stock is currently owned by institutional investors.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.